Vesugen

Preclinical Research

Vesugen (Lys-Glu-Asp)

A Khavinson bioregulator tripeptide targeting vascular endothelium, researched for blood vessel health.

Subcutaneous injectionBioregulatorCardiovascular

Dose

0.1 mg

Route

Subcutaneous injection

Cycle

10-20 days

Storage

2-8 °C (refrigerator)

What is Vesugen?

Vesugen (Glu-Asp-Arg) is a synthetic tripeptide derived from a sequence found in vascular endothelial cells. It belongs to the class of Khavinson peptides, also known as cytomedins or bioregulators, which are hypothesized to exert tissue-specific regulatory effects. Research, primarily in animal models and in vitro studies, suggests Vesugen may have a role in regulating vascular function and structure, potentially through interactions with gene expression involved in endothelial cell processes. It is not an FDA-approved drug and is considered a research chemical.

Key Benefits

Vascular endothelium research

🐾 Griffin Says...

Vesugen is the vascular-tissue Khavinson peptide. As with the rest of the family, the supporting literature is small, single-source and preclinical. Low cost and easy handling do not make up for an evidence base this thin.

Molecular Information

Molecular weight

364.36 g/mol

Type

Bioregulator Peptide

Amino acid sequence

Glu-Asp-Arg

Also known as Khavinson peptide 'Vesugen'.

Research Indications

Vascular Endothelium Function
Animal and in vitro studies suggest Vesugen may influence gene expression and protein synthesis in endothelial cells, potentially impacting vascular tone and integrity. Evidence: Animal/in-vitro only.
Blood Pressure Regulation
Some animal research indicates a potential role in modulating blood pressure, though specific mechanisms are still under investigation. Evidence: Animal/in-vitro only.

Research Protocols

Goal	Dose	Frequency	Route
General Vascular Support Research (Animal Models)	0.1 mg per day	Daily	Subcutaneous
Investigating Endothelial Gene Expression (In vitro/Animal)	0.01 - 0.1 mg/kg (animal), or nM concentrations (in vitro)	As per study design (e.g., daily for 10-20 days)	Subcutaneous (animal), or direct to cell culture (in vitro)
Blood Pressure Modulation Research (Animal Models)	0.05 - 0.1 mg per day	Daily for a defined period (e.g., 10 days)	Subcutaneous

In research settings, cycles are typically administered once or twice annually, or as needed based on the study's objectives and observed outcomes.

Peptide Interactions

Anticoagulants (e.g., Warfarin, Heparin)
Theoretical concern due to potential effects on vascular integrity; monitoring of coagulation parameters may be prudent in animal studies. Evidence: Theoretical/Preclinical.
Monitor Combination
Antiplatelet drugs (e.g., Aspirin, Clopidogrel)
Similar to anticoagulants, potential for additive effects on blood rheology; monitor for signs of bruising or bleeding in animal subjects. Evidence: Theoretical/Preclinical.
Monitor Combination
Vasodilators/Vasoconstrictors
Vesugen is hypothesized to affect vascular function; concomitant use with other vasoactive compounds in animal models requires careful observation for synergistic or antagonistic effects. Evidence: Theoretical/Preclinical.
Monitor Combination

How to Reconstitute

1Gather supplies: Vesugen vial, bacteriostatic water (BW), sterile syringe (e.g., 1 mL or 3 mL), sterile needles (e.g., 18-20 gauge for drawing, 29-31 gauge for injection), alcohol wipes.
2Clean vial tops: Swab the rubber stoppers of both the Vesugen vial and the bacteriostatic water vial with alcohol wipes.
3Draw BW: Using a sterile syringe with an appropriate gauge needle, draw the desired amount of bacteriostatic water (e.g., 1 mL) from its vial.
4Inject BW into peptide vial: Carefully inject the bacteriostatic water into the Vesugen vial, directing the stream against the inside wall of the vial to prevent direct impact on the lyophilized powder.
5Allow to dissolve: Do not shake. Gently swirl the vial between your fingers until the powder is completely dissolved. This may take a few minutes.
6Inspect solution: Ensure the solution is clear and free of particulate matter. If not, discard.

Avoid shaking the vial vigorously, as this can denature the peptide. Gently swirl until completely dissolved.

What to Expect

No immediate subjective sensations upon injection are typically reported.
Cumulative effects are theorized to manifest over weeks or months following a completed research cycle, rather than acutely.
Research aims to observe potential modulation of vascular health biomarkers in animal models.
Potential for minor, localized irritation at the injection site, typical of subcutaneous injections.

Side Effects & Safety

Vesugen is a research chemical; its safety and efficacy in humans have not been established by regulatory bodies like the FDA.
Strict aseptic technique is crucial during reconstitution and administration to prevent infection.
Proper disposal of needles and syringes is essential to prevent accidental injury or contamination.
Potential for localized skin reactions (redness, swelling, itching) at the injection site.
Keep out of reach of children and pets.
Do not use if the lyophilized powder or reconstituted solution appears discolored or contains particulate matter.

Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾

Open Calculator

Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.